European Union recommends Pfizer-BioNTech vaccine for 12-15 year olds

Photo: Shutterstock

The European Medicines Agency (EMA) has approved the use of the Pfizer-BioNTech Covid-19 vaccine for children aged 12 to 15.

Pfizer-BioNTech becomes the first vaccine to be authorised for adolescents in the 27 member states of the European Union (EU), reports Xinhua news agency.

Addressing a press conference here on Friday, Marco Cavaleri, EMA's vaccine strategy manager, said that the medicines' regulator had received the necessary data to authorise the vaccine for younger teens.

The data shows that it is highly effective against Covid-19.

He pointed out that the decision needs to be approved by the European Commission and individual national regulators.

Regulators in Canada and the US had already recommended its use for teenagers.

The EMA's recommendation was based on a study in more than 2,200 adolescents in the US showing that the vaccine was safe and effective.

The trial showed that the immune response in this group was comparable to that in the 16-25 age group.

The study shows that the vaccine was 100 per cent effective at preventing Covid, the EMA said in a statement.

The most common side effects in children aged 12 to 15 are similar to those in people aged 16 and above.

They include pain, tiredness, headache, muscle and joint pain, chills and fever.

--IANS

ksk/

 


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel